Stoke Therapeutics (STOK)
NASDAQ:STOK
Want to see STOK full AI Analyst Report?
Top Page
Stoke Therapeutics
(NASDAQ:STOK)
Select Model
Select Model
Rating:49Neutral
Price Target:
$29.00
▼(-22.19% Downside)
Action:Reiterated
Date:05/09/26
The score is held down primarily by weak and volatile operating fundamentals (sharp TTM revenue decline, very large losses, and heavy cash burn), partially offset by a strong, low-debt balance sheet. Technical indicators also lean bearish (below key moving averages with negative MACD). Valuation and corporate events provide only modest support given ongoing losses and limited valuation signals.
Positive Factors
Low Leverage / Balance Sheet
A near-zero debt profile and sizable equity position provide durable financial flexibility for a clinical-stage biotech. This reduces default risk, supports continued R&D spending through trial inflection points, and enables strategic options (partnering, milestone financing, opportunistic deals) over the next several quarters without forcing immediate dilution.
Negative Factors
Sharp Revenue Decline
An ~83% TTM revenue drop and deeply negative margins signal structurally weak operating performance. Such steep declines reduce internal funding capacity for pivotal trials, increase dependence on external financing, and make it harder to demonstrate a clear commercial trajectory for investors and partners over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Balance Sheet
A near-zero debt profile and sizable equity position provide durable financial flexibility for a clinical-stage biotech. This reduces default risk, supports continued R&D spending through trial inflection points, and enables strategic options (partnering, milestone financing, opportunistic deals) over the next several quarters without forcing immediate dilution.
Read all positive factors
Stoke Therapeutics (STOK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.83B
Dividend YieldN/A
Average Volume (3M)548.71K
Price to Earnings (P/E)―
Beta (1Y)1.54
Revenue Growth-83.20%
EPS Growth-439.48%
CountryUS
Employees128
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.83
Shares Outstanding62,281,654
10 Day Avg. Volume636,975
30 Day Avg. Volume548,706
Financial Highlights & Ratios
PEG Ratio2.94
Price to Book (P/B)5.33
Price to Sales (P/S)10.19
P/FCF Ratio41.85
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue52.22
Enterprise Value/Gross Profit57.78
Enterprise Value/Ebitda-9.40
Forecast
1Y Price Target
$47.83Price Target Upside28.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-3.38
Revenue Forecast (FY)$27.16M
Stoke Therapeutics Business Overview & Revenue Model
Company Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targe...
How the Company Makes Money
Stoke Therapeutics does not currently generate meaningful recurring revenue from product sales and has historically operated at a loss while funding research and development. Its revenue, when present, primarily comes from collaboration and licens...
Stoke Therapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
74
Positive
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 32.08M | 184.42M | 36.55M | 8.78M | 12.40M | 0.00 |
| Gross Profit | 28.99M | 184.42M | 36.55M | 8.78M | 12.40M | 0.00 |
| EBITDA | -178.24M | -18.82M | -99.19M | -112.30M | -102.81M | -85.09M |
| Net Income | -169.77M | -6.88M | -88.98M | -104.70M | -101.07M | -85.81M |
Balance Sheet | ||||||
| Total Assets | 443.28M | 418.43M | 271.56M | 228.34M | 256.07M | 238.87M |
| Cash, Cash Equivalents and Short-Term Investments | 343.55M | 284.67M | 216.90M | 201.39M | 229.59M | 219.81M |
| Total Debt | 3.42M | 0.00 | 2.32M | 2.06M | 2.36M | 1.51M |
| Total Liabilities | 48.40M | 65.98M | 42.53M | 68.78M | 71.22M | 21.09M |
| Stockholders Equity | 394.88M | 352.46M | 229.02M | 159.56M | 184.85M | 217.78M |
Cash Flow | ||||||
| Free Cash Flow | -147.69M | 44.91M | -87.05M | -82.68M | -35.83M | -68.11M |
| Operating Cash Flow | -146.82M | 45.59M | -86.85M | -81.07M | -31.87M | -66.91M |
| Investing Cash Flow | -149.75M | -186.81M | -107.47M | 105.95M | -45.88M | -76.43M |
| Financing Cash Flow | 180.34M | 97.39M | 131.09M | 53.01M | 46.41M | 1.28M |
Stoke Therapeutics Technical Analysis
Negative
37.27
Price Trends
33.15
Negative
32.94
Negative
29.63
Negative
Market Momentum
-1.19
Positive
33.83
Neutral
29.49
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STOK, the sentiment is Negative. The current price of 37.27 is above the 20-day moving average (MA) of 31.90, above the 50-day MA of 33.15, and above the 200-day MA of 29.63, indicating a bearish trend. The MACD of -1.19 indicates Positive momentum. The RSI at 33.83 is Neutral, neither overbought nor oversold. The STOCH value of 29.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for STOK.
Stoke Therapeutics Risk Analysis
Stoke Therapeutics disclosed 67 risk factors in its most recent earnings report. Stoke Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Stoke Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $1.07B | 110.68 | 735.00% | ― | 41.47% | ― | |
60 Neutral | $1.80B | -18.61 | -24.79% | ― | ― | -18.14% | |
55 Neutral | $1.86B | -16.81 | -27.31% | ― | ― | -27.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.83B | -10.27 | -48.84% | ― | -83.20% | -439.48% | |
49 Neutral | $1.77B | -11.85 | -256.66% | ― | 397.28% | 27.68% |
* Healthcare Sector Average
STOK
Stoke Therapeutics
29.34
19.98
213.46%
SNDX
Syndax Pharmaceuticals
19.94
10.09
102.44%
XERS
Xeris Pharmaceuticals
6.19
1.36
28.16%
RAPP
Rapport Therapeutics, Inc.
37.72
27.68
275.70%
SION
Sionna Therapeutics, Inc.
41.13
28.05
214.45%
Stoke Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Stoke Therapeutics Adds Veteran Leader to Board, R&D Oversight
Positive
Apr 7, 2026
On April 3, 2026, Stoke Therapeutics’ board expanded to ten members and appointed veteran drug development and regulatory executive Clare Kahn, Ph.D., as an independent Class I director, with her term running until the 2026 annual shareholde...
Executive/Board ChangesFinancial Disclosures
Stoke Therapeutics Awards Discretionary Bonus to CEO Smith
Positive
Mar 3, 2026
On February 13, 2026, Stoke Therapeutics’ board approved a discretionary bonus of $697,125 for Chief Executive Officer Ian F. Smith, matching his full target annual bonus for 2025 despite his non-participation in the regular annual bonus pro...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.